Tenderwize
Zurück zur Suche

Open-house biologics rebate agreement for Natalizumab (subcutaneous formulation)

Techniker Krankenkasse·Hamburg, Germany·Deadline Jan 30, 2028 · 524 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-36 - Natalizumab (Darreichungsform zur subkutanen Injektion)

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

58 / 100

Risikofaktoren

Contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature or by...

Participation is limited to pharmaceutical undertakings for the relevant medicinal product and requires valid authorisa...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Conclusion of pharmaceutical rebate agreements for Natalizumab (subcutaneous injection formulation).
  • Open-house arrangement with uniform contractual conditions and no individual negotiations.
Vollständige Zusammenfassung anzeigen

Open-house pharmaceutical supply arrangement for Natalizumab (subcutaneous formulation) in Germany, led by Techniker Krankenkasse with HEK and hkk as participating buyers. The notice states that any suitable pharmaceutical undertaking may join during the contract period, with no exclusivity and no individual negotiations. The contract runs for up to 24 months from 01.02.2026 and ends no later than 31.01.2028. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the documents are only available electronically. No contract value is stated.

Risiken

Contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature or by...

Participation is limited to pharmaceutical undertakings for the relevant medicinal product and requires valid authorisa...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal product(s).
  • Applicant must have its seat in Germany, another EU Member State, or another EEA State.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product(s), or otherwise be entitled to place them on the market in its own name.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house biologics rebate agreement for Natalizumab (subcutaneous formulation)

Single lot covering the conclusion of pharmaceutical rebate agreements under Section 130a(8) SGB V for Natalizumab in subcutaneous formulation. Scope is nationwide in Germany. The notice says the arrangement is open-house, with uniform terms, no exclusivity, and no individual negotiations. Lot information is taken from structured data and the notice text.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Jan 2026 - Jan 2028

Kategorie

Pharmaceutical products

Frist

Deadline Jan 30, 2028

Vergabedetails

Veröffentlichungsdatum
23 Nov 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
776899-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3